1
|
Poissonnet V, Chabrillac E, Uro-Coste E, Woisard V, Moya-Plana A, Espitalier F, Castelli J, Dedieu T, Salas S, Garrel R, Baudouin R, Poissonnet G, Castain C, Barbut J, Mirghani H, Evrard D, Bouchain O, Marie JP, Orliac H, Ceruse P, Dufour X, Brenet E, Rambeau A, Herman P, Abu Shama Y, Bertolus C, Atallah S, Morinière S, Righini C, Mouawad F, Duflo S, Segier B, Vergez S. Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study. Oral Oncol 2024; 159:107072. [PMID: 39432991 DOI: 10.1016/j.oraloncology.2024.107072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 09/30/2024] [Accepted: 10/04/2024] [Indexed: 10/23/2024]
Abstract
INTRODUCTION Salivary carcinomas of the tongue represent a therapeutic challenge as their radical excision is particularly mutilating. We aimed to study the oncologic and functional outcomes of advanced stages salivary carcinomas of the tongue. MATERIALS AND METHODS This retrospective multicentric study, based on the French national network on rare head and neck cancers (REFCOR), included all patients with a T3-T4 salivary carcinoma of the tongue, diagnosed between January 2009 and December 2018. RESULTS In total, 47 patients were included, of which 44.7 % underwent surgery. Histologies were mostly adenoid cystic carcinomas (61.7 %), followed by other adenocarcinomas (27.7 %) and mucoepidermoid carcinomas (10.6 %). Median follow-up duration was 63.9 months. In multivariable analysis, surgery was significantly associated with better Recurrence-Free Survival (HR = 0.23, 95 %CI [0.09;0.55]) and Local/Regional Recurrence-Free Survival (HR = 0.31, 95 %CI [0.10;0.95]). The rate of distant metastasis at the end of follow-up was 61.9 % in the surgical group and 57.7 % in the non-surgical group. The Distant Metastasis Free Survival was 54.9 % [38.3;68.7], without statistical difference between both groups. There were similar rates of definitive gastrostomies but the rate of normal oral diet at the last follow-up seemed higher in the surgery group (38.1 % vs 15.4 %). CONCLUSION Radical surgery in that population mainly aims to improve local/regional control, which may result in better long-term swallowing functions. About half of these tumors may be associated with occult distant metastasis at initial presentation. More studies are warranted to establish the role of postoperative RT and non-surgical treatment with concurrent CRT.
Collapse
Affiliation(s)
- Valentine Poissonnet
- Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.
| | - Emilien Chabrillac
- Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France
| | - Emmanuelle Uro-Coste
- Department of Anatomical Pathology, University Cancer Institute Toulouse, Toulouse France
| | - Virginie Woisard
- Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France
| | - Antoine Moya-Plana
- Head and Neck Oncology Department, Gustave-Roussy Institute, Villejuif, France
| | - Florent Espitalier
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Nantes, France
| | - Joel Castelli
- Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France
| | - Thibault Dedieu
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Strasbourg, France
| | - Sébastien Salas
- AP-HM, Aix-Marseille University, Department of Medical Oncology, Marseille, France
| | - Renaud Garrel
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Montpellier, France
| | - Robin Baudouin
- Otolaryngology, Head and Neck Surgery Department, Foch Hospital, Paris, France
| | - Gilles Poissonnet
- Otolaryngology, Head and Neck Surgery Department, Head and Neck University Institute, Nice, France
| | - Claire Castain
- Department of Anatomical Pathology, Bordeaux University Hospital-CHU, F-33000, Bordeaux, France
| | - Jonathan Barbut
- Otolaryngology, Head and Neck Surgery Department, Hospital of Toulon, France
| | - Haitham Mirghani
- Otolaryngology, Head and Neck Surgery Department, George Pompidou European Hospital, Paris, France
| | - Diane Evrard
- Otolaryngology, Head and Neck Surgery Department, Bichat Hospital, Paris, France
| | - Olivier Bouchain
- Head and Neck Surgery Department, CHU Sart Tilman, University Liege, Belgium
| | - Jean Paul Marie
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Rouen, France
| | - Hélène Orliac
- Department of Radiation Therapy, University Hospital of Limoges, France
| | - Philippe Ceruse
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Lyon, France
| | - Xavier Dufour
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Poitiers, France
| | - Esteban Brenet
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Reims, France
| | - Audrey Rambeau
- Oncology Department, François Baclesse Centre, Caen, France
| | - Philippe Herman
- Otolaryngology, Head and Neck Surgery Department, Lariboisière Hospital, 2 rue Ambroise Paré, 75010 Paris, France
| | - Yazan Abu Shama
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Nancy, France
| | - Chloé Bertolus
- Department of Oral and Maxillo-Facial Surgery, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université, France
| | - Sarah Atallah
- Head and Neck Surgery Department, Tenon Hospital, APHP, Sorbonne University, Paris, France
| | - Sylvain Morinière
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Tours, France
| | - Christian Righini
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Grenoble, France
| | - François Mouawad
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Lille, France
| | - Suzy Duflo
- Otolaryngology, Head and Neck Surgery Department, University Hospital of Point-à-Pitre, France
| | - Bertille Segier
- Statistical Department, Institut Claudius Regaud, University Institute of Cancer, Toulouse, France
| | - Sébastien Vergez
- Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France
| |
Collapse
|
2
|
Li P, Zhang X, Fang Q, Du W. Sentinel lymph node biopsy in cT1-2N0 minor salivary gland cancer in oral cavity. BMC Cancer 2024; 24:1349. [PMID: 39497070 PMCID: PMC11533395 DOI: 10.1186/s12885-024-13107-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2024] [Accepted: 10/24/2024] [Indexed: 11/06/2024] Open
Abstract
OBJECTIVE To evaluate the efficacy of sentinel lymph node biopsy (SLNB) in cT1/2N0 minor salivary gland cancer (mSGC) located within the oral cavity. METHODS A retrospective analysis was conducted on patients diagnosed with cT1/2N0 oral mSGC, who were categorized into two groups based on neck management approaches. The impact of SLNB versus observation on regional control and overall survival was assessed using a Cox model. RESULTS A total of 177 patients were included in the study, with 53 cases undergoing SLNB. All patients had at least one sentinel lymph node, with the majority having two sentinel lymph nodes. The sentinel lymph nodes were predominantly situated in level I, followed by level II. Four patients had positive sentinel lymph nodes, all of whom had primary tumors in the tongue or the floor of the mouth, and were classified as cT2 stage. This yielded a sensitivity and specificity of 100%, a false negative rate of 0%, and a negative predictive value of 100% for SLNB in predicting occult metastasis. In terms of regional control, SLNB exhibited a reduced hazard ratio of 0.90 (95% confidence interval: 0.64-0.96) compared to observation. However, SLNB did not confer a superior overall survival benefit compared to observation. CONCLUSION In patients with cT1/2N0 oral mSGC, SLNB proved to be both technically feasible and oncologically safe. When contrasted with observation, SLNB was associated with enhanced regional control, particularly recommending its use for cases of cT2 mSGC arising from the tongue or the floor of the mouth.
Collapse
Affiliation(s)
- Peng Li
- Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, PR China
| | - Xu Zhang
- Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, PR China
| | - Qigen Fang
- Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, PR China
| | - Wei Du
- Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, PR China.
| |
Collapse
|
3
|
Vergez S, Chabrillac E, Fakhry N. Salivary gland cancer: Recommendations by formal consensus, for the French Network of Rare Head and Neck Tumors (REFCOR). Eur Ann Otorhinolaryngol Head Neck Dis 2024; 141:3-4. [PMID: 38092570 DOI: 10.1016/j.anorl.2023.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2024]
Affiliation(s)
- S Vergez
- Département de chirurgie ORL et cervico-faciale, CHU de Toulouse-Larrey, université Toulouse III Paul-Sabatier, Toulouse, France; Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France.
| | - E Chabrillac
- Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France
| | - N Fakhry
- Département de chirurgie ORL et cervico-faciale, Aix-Marseille université, hôpital La Conception, AP-HM, Marseille, France
| |
Collapse
|